Conference Coverage

Lenalidomide improves PFS after 1st and 2nd line CLL therapy

Publish date: December 14, 2016

 

AT ASH 2016

Pages

Recommended Reading

Ibrutinib at below standard dose may achieve good survival in CLL
B-Cell Lymphoma ICYMI
Acalabrutinib shows efficacy as monotherapy in untreated CLL
B-Cell Lymphoma ICYMI
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
B-Cell Lymphoma ICYMI
CAR T-cell therapy eyed for CLL patients with residual disease
B-Cell Lymphoma ICYMI
CLL: Genetic aberrations predict poor treatment response in elderly
B-Cell Lymphoma ICYMI
Survival in CLL predicted by minimum residual disease
B-Cell Lymphoma ICYMI
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
B-Cell Lymphoma ICYMI
Minimal residual disease status predicts 10-year survival in CLL
B-Cell Lymphoma ICYMI
Targeted therapies predicted to blow out costs for CLL
B-Cell Lymphoma ICYMI
Idelalisib held unlikely to become frontline therapy for CLL
B-Cell Lymphoma ICYMI